MedTrace Logo

EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings

NCT07056036 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-12-10

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate if the treatment with ExoMIND (BTL-699-2) device is able to improve willpower, self-control and food cravings in adults above the age of 22 years. The main question it aims to answer is:

Does the treatment with EXOMIND (BTL-699-2) device improve willpower, self-control and food cravings?

Participants will be asked to:

* Undergo six treatments
* Complete the Brief Self-control Scale
* Complete the Food Cravings Questionnaire - Trait
* Complete the Therapy Comfort Questionnaire
* Complete the Subject Satisfaction Questionnaire

Conditions

  • Self-Control
  • Food Cravings

Interventions

DEVICE

ActiveTreatment with BTL-699-2

Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.

DEVICE

Sham Treatment with BTL-699-2

Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will se to 5% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.

Sponsors & Collaborators

  • BTL Industries Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-10-10
Completion
2025-10-10
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07056036 on ClinicalTrials.gov